InventisBio (SH:688382) Ge Long Hui·2026-02-26 10:16Core Viewpoint - The company Yifang Biotech (688382.SH) is expected to report a revenue of 373.25 million yuan for the fiscal year 2025, with a net loss attributable to shareholders of 317 million yuan, primarily influenced by high R&D investment and revenue composition [1][2]. Group 1: Financial Performance - The company anticipates a revenue of 373.25 million yuan for 2025 [1]. - The net profit attributable to the parent company is projected to be a loss of 317 million yuan [1]. Group 2: R&D Progress - The company has made significant progress in its R&D pipeline, with several core clinical projects entering critical stages [1]. - The oral selective estrogen receptor degrader (SERD) D-0502 is undergoing Phase III clinical trials for second-line treatment in China [1]. - The TYK2 inhibitor D-2570 has initiated clinical explorations in multiple autoimmune disease areas, including ongoing Phase II trials for ulcerative colitis and Phase III trials for psoriasis in China, as well as Phase I trials in the U.S. [1]. - The URAT1 inhibitor D-0120 has completed follow-up for its Phase II clinical trials in the U.S., with all research expected to be completed by Q1 2026 [1]. Group 3: Early Development and Future Outlook - The company has achieved key advancements in its preclinical pipeline, with two innovative candidates, WRN inhibitor YF087 and KIF18A inhibitor YF550, showing promising anti-tumor potential [2]. - Ongoing IND supportive research is being conducted to prepare these candidates for clinical stages [2]. - The company continues to invest in early-stage R&D, including the development of other candidates and innovative technology platforms, to build momentum for long-term growth [2]. - Despite high R&D expenditures, the company expects to incur losses in 2025 as technology licensing and collaboration revenues do not cover costs and expenses [2].